Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections

This study has been completed.
Information provided by (Responsible Party):
Basilea Pharmaceutica Identifier:
First received: September 27, 2005
Last updated: July 25, 2012
Last verified: July 2012
The purpose of this study is to compare the clinical cure rate of ceftobiprole medocaril versus a comparator in the treatment of patients with complicated skin and skin structure infections.

Condition Intervention Phase
Skin Diseases, Infectious
Skin Diseases, Bacterial
Staphylococcal Skin Infections
Drug: Ceftobiprole medocaril
Drug: Vancomycin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III, Randomized, Double-Blind Study of Ceftobiprole Versus Comparator in the Treatment of Complicated Skin and Skin Structure Infections

Resource links provided by NLM:

Further study details as provided by Basilea Pharmaceutica:

Primary Outcome Measures:
  • Clinical outcome (cure, failure, not evaluable) at 7-14 days after the end of therapy. [ Time Frame: 7 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Microbiological outcome at 7-14 days after the end of therapy. Clinical and microbiological outcome at late follow-up visit. Evolution of signs and symptoms of disease. Time to clinical cure. Safety and tolerability evaluations during the study. [ Time Frame: 7 weeks ] [ Designated as safety issue: No ]

Enrollment: 784
Study Start Date: October 2004
Study Completion Date: December 2005
Primary Completion Date: December 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ceftobiprole medocaril
Ceftobiprole medocaril 500mg q12h as 1h infusion, 7-14d
Drug: Ceftobiprole medocaril
Active Comparator: Vancomycin
Vancomycin 1g q12h as 1h infusion, 7-14d
Drug: Vancomycin

Detailed Description:
Ceftobiprole medocaril is a cephalosporin antibiotic with anti-MRSA (Methicillin-Resistant Staphylococcus Aureus) activity. Ceftobiprole medocaril is not yet approved for the treatment of complicated skin and skin structure infections. This is a randomized, double-blind, multicenter study of ceftobiprole medocaril plus placebo versus a comparator to assess the effectiveness and safety of ceftobiprole medocaril in patients with complicated skin and skin structure infections. The patients will be randomized to ceftobiprole medocaril plus placebo or a comparator. The primary endpoint is the clinical cure rate of ceftobiprole medocaril at the test-of-cure visit. The patients will receive either ceftobiprole medocaril plus placebo or a comparator for 7 to 14 days (unless extended at discretion of medical monitor).

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of an infection consistent with complicated skin and skin structure infections.

Exclusion Criteria:

  • Known or suspected hypersensitivity to any study medication
  • Any known or suspected condition or concurrent treatment contraindicated by the prescribing information
  • Previous enrollment in this study
  • Treatment with any investigational drug within 30 days before enrollment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00228982

Sponsors and Collaborators
Basilea Pharmaceutica
Study Director: Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
  More Information

Responsible Party: Basilea Pharmaceutica Identifier: NCT00228982     History of Changes
Other Study ID Numbers: CR005038  BAP00154 
Study First Received: September 27, 2005
Last Updated: July 25, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Basilea Pharmaceutica:
Complicated Skin Infections
Infectious Skin Diseases
Bacterial Skin Diseases
Staphylococcal Skin Infections

Additional relevant MeSH terms:
Communicable Diseases
Skin Diseases
Skin Diseases, Infectious
Staphylococcal Skin Infections
Skin Diseases, Bacterial
Staphylococcal Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Ceftobiprole medocaril
Anti-Bacterial Agents
Anti-Infective Agents processed this record on January 18, 2017